Navigation Links
'Nanosponge vaccine' fights MRSA toxins
Date:12/1/2013

fore, use a heat or chemically processed version of the toxin that unravels some of its proteins and makes it a little weaker. But this process also makes the immune response to the toxin a little weaker.

"The more you heat it, the safer the toxin is, but the more you heat it, the more you damage the structure of the protein," Zhang explained. "And this structure is what the immune cell recognizes, and builds its antibodies against."

The nanosponge toxoid vaccine gets around this problem by detainingbut not changingthe staph toxin. Like a dangerous but handcuffed prisoner, the staph toxin can be led to the dendritic cells of the immune system without causing any harm.

Before this, "there was no way you could deliver a native toxin to the immune cells without damaging the cells," Zhang said. "But this technology allows us to do this."

Each vaccine particle is approximately 85 nanometers in diameter; for comparison, about 1000 of them would fit across the width of a single human hair. They are cleared from the body after injection in about two weeks, the researchers found.

Staphylococcus aureus

Staph bacteria are one of the most common causes of skin infections, and can cause blood poisoning and surgical infections as well as pneumonia. According to the Centers for Disease Control and Prevention, about 80,000 Americans suffer from invasive MRSA infections each year, and over 11,000 of those individuals die. At the moment, there are no vaccines approved to protect humans against the toxins associated with staph infections, including those caused by MRSA strains.

The idea for a staph vaccine came about when the researchers considered the success of their nanosponge. If the particle was so good at collecting toxins, they wondered, what were the potential uses of a particle full of toxin? "To be honest, we never thought about the vaccine use from the beginning," Zhang noted. "But when we do research, we
'/>"/>

Contact: Daniel Kane
dbkane@ucsd.edu
858-534-3262
University of California - San Diego
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Nanosponges soak up oil again and again
2. New malaria vaccines roadmap targets next generation products by 2030
3. A new DNA vaccine induces a Th2 immune response in Alzheimers disease mice
4. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
5. Reassuring findings released in national study of influenza vaccine safety in pregnancy
6. New investment fund will advance late-stage vaccines, other global health technologies
7. Scientists closer to universal flu vaccine after pandemic natural experiment
8. University of Maryland researchers studying vaccine to prevent potential bird flu pandemic
9. Scientists engineer strain of MERS coronavirus for use in a vaccine
10. IDRI and Zydus sign agreement for development of IDRIs vaccine candidate for visceral leishmaniasis
11. New materials, progress toward an HIV vaccine, and more at meeting of crystallographers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Nanosponge vaccine' fights MRSA toxins
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... the October 2011 issue of Experimental Biology and ... Medical Center led by Stephen Tsang, MD, Ph.D have ... model for retinitis pigmentosa (RP) using novel bipartite gene ... by progressive degeneration of rod photoreceptors (which mediate night ...
... The carbon dioxide we exhale and the odors our skins ... hunt for human hosts to bite and spread diseases such ... at the University of California, Riverside have now performed experiments ... that transmit yellow fever and dengue -- respond to plumes ...
... Irvine, Calif., Sept. 30, 2011 A glucosamine-like dietary ... sclerosis, according to a UC Irvine study. UCI,s ... oral N-acetylglucosamine (GlcNAc), which is similar to but more ... and function of abnormal T-cells that in MS incorrectly ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3Flight patterns reveal how mosquitoes find hosts to transmit deadly diseases 2Glucosamine-like supplement suppresses multiple sclerosis attacks 2
(Date:4/16/2015)... 2015 Regis Technologies looks forward to ... Cancer Research (AACR) annual meeting. Regis will exhibit at ... Saturday, April 18, in Philadelphia and running through April ... of the oldest and largest organization focused on cancer ... and partners with survivors to promote awareness and research ...
(Date:4/16/2015)... , April 16, 2015  In recognition of World Hemophilia ... hemophilia advocacy groups to illuminate more than 15 prominent landmarks ... Boston,s Zakim Bridge and Prudential Tower, ... Orleans, Mercedes-Benz Superdome and Denver,s ... the evening of April 17, and coincide with hemophilia community ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... Oct. 31, 2011 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... 30, 2011. For the third quarter of 2011, ... fully diluted share outstanding, compared to net income of $3.3 million, ... in 2010. For the nine months ended September 30, 2011, the ...
... (NYSE Amex: PIP ) announced today further ... SparVax™.  The new vaccine is being developed to provide ... emergency.  The Company completed its first cGMP manufacturing run ... ongoing and expected to be completed in December. ...
... Blood Pressure , aka Hypertension , is ... mostly ineffective.   Fortunately , Hypertensive patients ... methods that are both effective, inexpensive, and risk free. ... help reduce   Chronic Heart/Cardiovascular Disease patients,   ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8PharmAthene Progresses Second Generation rPA Anthrax Vaccine 2PharmAthene Progresses Second Generation rPA Anthrax Vaccine 3PharmAthene Progresses Second Generation rPA Anthrax Vaccine 4Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: